Correction: TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

In Table 1 of the original version of this article (1), some values in the second row (Venetoclax + azacitidine or 5-day decitabine) were omitted or incorrect. “Study phase” should be Ib/II, III, “TP53-mutated pts” should be 36, 54, “Response” should be CR/CRi 47%, 41%, and “CR rate” should be NR, 20%. The values in Table 1 have been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.